오피오이드 시장 : 오피오이드 종류, 투여 방법, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Opioids Market was valued at USD 10.88 billion in 2024 and is projected to grow to USD 11.44 billion in 2025, with a CAGR of 5.24%, reaching USD 14.79 billion by 2030.

The opioids market stands at a crossroads of evolving patient needs, regulatory reform, and advanced research and development. In this analysis, we explore the market's current state and future potential, highlighting the pivotal factors that continue to shape its trajectory. Over the past few years, nuances in clinical practices and treatment protocols have necessitated a thorough reexamination of both supply and demand dynamics. Market participants, including healthcare providers and policy regulators, are being urged to balance the critical need for effective pain management with the broader imperative of patient safety. Increasingly, data-driven decisions are guiding innovations in therapy, treatment delivery, and risk management. This comprehensive review lays the groundwork for understanding the market's intricate landscape, examining the interplay between scientific progress and economic factors. As the industry navigates complex social, regulatory, and technical challenges, it is essential to align investment with evidenced-based strategies. This overview sets the stage for a deeper dive into transformative shifts, segmentation insights, and regional and company-specific dynamics that provide a holistic picture of the opioids market.

Transformative Shifts Redefining the Opioids Market

Recent transformative shifts in the market have redefined how stakeholders perceive and engage with opioids. Rapid changes in regulatory frameworks and a renewed focus on patient-centric care have led to significant realignments. Traditional distribution channels are being optimized through technological integration, enabling faster access to high-quality formulations while maintaining stringent safety protocols. Emerging research is driving a paradigm shift from broad-spectrum opioid applications to more targeted treatment regimens. This evolution underscores the importance of adaptive business models that can swiftly respond to changing clinical guidelines and patient demographics. In parallel, industry innovation continues to bridge the gap between therapeutic efficacy and risk management. Economic pressures and competitive forces are fostering collaborations between research institutions and pharmaceutical companies, cementing a future where precision therapies and personalized medicine dominate. Such adaptive measures are not simply reactive; they are proactive responses to long-standing market challenges. The convergence of enhanced scientific research, improved patient monitoring protocols, and digital healthcare solutions has amplified market efficiency, ensuring that therapeutic advances reach the patient while reinforcing compliance and ethical practices.

Comprehensive Segmentation Insights Shaping Market Analysis

A detailed examination of the market reveals insights that stem from a multi-faceted segmentation framework. When considering opioid types, the market analysis distinguishes among natural opiates, semi-synthetic opioids, and synthetic opioids. The natural opiates category is further nuanced by its study of codeine and morphine, whereas semi-synthetic opioids are dissected with a focus on hydrocodone and oxycodone. Synthetic opioids, a rapidly evolving segment, are characterized by distinct subcategories such as fentanyl and methadone. Beyond the chemical classification, the analysis extends to modes of administration, where oral delivery including capsules and tablets plays a significant role alongside parenteral routes like intramuscular and intravenous methods, and the increasingly adopted transdermal approaches. Application-based segmentation further elaborates distinct clinical segments such as anesthesia, which is methodically divided into general and regional anesthesia, and pain management, which addresses both acute and chronic conditions. Finally, an end-user analysis investigates the nuances among healthcare facilities, noted for their dual focus on clinics and hospitals, home healthcare, and research institutes. This multifaceted segmentation provides a granular view that informs both strategic decision-making and operational planning.

Based on Opioid Types, market is studied across Natural Opiates, Semi-Synthetic Opioids, and Synthetic Opioids. The Natural Opiates is further studied across Codeine and Morphine. The Semi-Synthetic Opioids is further studied across Hydrocodone and Oxycodone. The Synthetic Opioids is further studied across Fentanyl and Methadone.

Based on Mode of Administration, market is studied across Oral Administration, Parenteral Administration, and Transdermal Administration. The Oral Administration is further studied across Capsules and Tablets. The Parenteral Administration is further studied across Intramuscular and Intravenous.

Based on Application, market is studied across Anesthesia, Cough Suppression, and Pain Management. The Anesthesia is further studied across General Anesthesia and Regional Anesthesia. The Pain Management is further studied across Acute Pain and Chronic Pain.

Based on End-User, market is studied across Healthcare Facilities, Home Healthcare, and Research Institutes. The Healthcare Facilities is further studied across Clinics and Hospitals.

Key Regional Dynamics Influencing Market Growth

The opioids market exhibits distinct regional characteristics driven by varied economic, regulatory, and healthcare factors. In the Americas, the market is influenced by robust healthcare systems and evolving policies that emphasize patient safety and innovation. Concurrently, regions spanning Europe, the Middle East, and Africa experience a blend of stringent regulatory oversight coupled with dynamic market opportunities, as diverse healthcare systems adapt to emerging treatment protocols. Meanwhile, Asia-Pacific stands out with its rapidly expanding pharmaceutical industries, heightened research capabilities, and significant investments in healthcare infrastructure. These regions collectively demonstrate unique growth trajectories, challenges, and opportunities that influence market behavior at both a macro and micro level. The interplay among these regions highlights the need for localized strategies that account for cultural, economic, and regulatory differences. As countries balance modernization with legacy systems, investors and key stakeholders are provided with a rich tapestry of market insights that underscore the importance of both global collaboration and regional specialization in achieving competitive advantage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation in the Opioids Market

The competitive landscape in the opioids market is marked by the strategic initiatives of several key industry leaders. Major players such as Abbott Laboratories and AbbVie Inc. are continuously refining their research and development processes to pioneer advanced therapeutic solutions. Companies like Accord Healthcare, Ltd. and Alkermes plc have initiated strategic collaborations to enhance both drug efficacy and safety profiles. Globally recognized entities, including AmerisourceBergen Corporation and Bristol Laboratories Limited, contribute to market dynamism by streamlining supply chains and adopting innovative distribution models. This landscape is further enriched by the initiatives of Johnson Matthey Plc, Mallinckrodt LLC, and Noramco, Inc., which are instrumental in translating research breakthroughs into marketable solutions. Omnica Laboratories, Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. round out the competitive narrative by emphasizing quality, compliance, and next-generation innovations. Through continuous investment in technology and research, these companies are shaping the future of the industry, undertaking rigorous measures to balance market growth with patient-centered care and global safety standards.

The report delves into recent significant developments in the Opioids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Accord Healthcare, Ltd., Alkermes plc, AmerisourceBergen Corporation, Bristol Laboratories Limited, Johnson Matthey Plc, Mallinckrodt LLC, Noramco, Inc., Omnica Laboratories, Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a proactive stance in navigating the complexities of the opioids market. It is imperative to invest in research and development initiatives that promote the creation of safer and more effective opioid formulations. Companies should focus on strengthening their quality assurance measures and expanding their portfolio through strategic partnerships and acquisitions. Embracing digital transformation can further streamline production, distribution, and patient monitoring processes, ensuring that innovations are rapidly integrated into clinical practice. In addition, fostering open collaboration with regulatory bodies will facilitate smoother market entry and sustained growth. It is also recommended that decision-makers prioritize market education and transparent communication strategies to build trust among stakeholders. These strategic interventions should be paired with robust risk management practices to mitigate potential liabilities. Emphasizing continuous improvement through feedback loops from clinical outcomes and market performance will empower companies to adapt in real time, ensuring they remain competitive in a swiftly evolving marketplace.

Conclusion and Forward-Looking Perspectives

In conclusion, the analysis of the opioids market provides a deep and insightful perspective into a sector that is critical to modern healthcare. The evolving dynamics, driven by both external regulatory pressures and internal innovation, are crafting a future that prioritizes patient safety, quality care, and scientific advancement. By dissecting the market through detailed segmentation and regional analysis, this review underscores the importance of a balanced approach that integrates clinical expertise with market intelligence. The competitive landscape, shaped by leading industry players, further highlights the necessity for agile strategies in the face of emerging challenges. As the market continues to evolve, stakeholders are urged to maintain a forward-looking perspective that embraces change and leverages data-driven insights for sustainable growth. This comprehensive review offers not just a summary of current trends, but a roadmap for navigating future opportunities in a complex and vital market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic and acute pain conditions drives up opioid medication consumption
    • 5.1.1.2. Expansion of healthcare infrastructure and services enhancing accessibility to opioid treatments
    • 5.1.1.3. Expanding pharmaceutical research and development contributes to the introduction of new opioids
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with opioid prescription management
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding telehealth services for opioid addiction counseling and treatment in underserved areas
    • 5.1.3.2. Developing mobile apps for opioid addiction recovery support and community connectivity
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations to control the prescription and distribution of opioids
• 5.2. Market Segmentation Analysis
  • 5.2.1. Opioid Types: Rising adoption of natural opiates due to their effective pain-relieving properties
  • 5.2.2. Application: Rising application of opioids in pain management to manage both acute and chronic pain conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Opioids Market, by Opioid Types

• 6.1. Introduction
• 6.2. Natural Opiates
  • 6.2.1. Codeine
  • 6.2.2. Morphine
• 6.3. Semi-Synthetic Opioids
  • 6.3.1. Hydrocodone
  • 6.3.2. Oxycodone
• 6.4. Synthetic Opioids
  • 6.4.1. Fentanyl
  • 6.4.2. Methadone

7. Opioids Market, by Mode of Administration

• 7.1. Introduction
• 7.2. Oral Administration
  • 7.2.1. Capsules
  • 7.2.2. Tablets
• 7.3. Parenteral Administration
  • 7.3.1. Intramuscular
  • 7.3.2. Intravenous
• 7.4. Transdermal Administration

8. Opioids Market, by Application

• 8.1. Introduction
• 8.2. Anesthesia
  • 8.2.1. General Anesthesia
  • 8.2.2. Regional Anesthesia
• 8.3. Cough Suppression
• 8.4. Pain Management
  • 8.4.1. Acute Pain
  • 8.4.2. Chronic Pain

9. Opioids Market, by End-User

• 9.1. Introduction
• 9.2. Healthcare Facilities
  • 9.2.1. Clinics
  • 9.2.2. Hospitals
• 9.3. Home Healthcare
• 9.4. Research Institutes

10. Americas Opioids Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Opioids Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Opioids Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. ANANDA Scientific announces a clinical trial evaluating Nantheia ATL5, in the treatment of co-occurring Opioid Use
  • 13.3.2. FDA approval of over-the-counter naloxone nasal spray by Amneal set to transform opioid overdose intervention accessibility
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Accord Healthcare, Ltd.
• 4. Alkermes plc
• 5. AmerisourceBergen Corporation
• 6. Bristol Laboratories Limited
• 7. Johnson Matthey Plc
• 8. Mallinckrodt LLC
• 9. Noramco, Inc.
• 10. Omnica Laboratories
• 11. Purdue Pharma L.P.
• 12. Sun Pharmaceutical Industries Ltd.
• 13. Teva Pharmaceutical Industries Ltd.
• 14. Viatris Inc.